MX2021001479A - Novedosos procesos y vacunas. - Google Patents

Novedosos procesos y vacunas.

Info

Publication number
MX2021001479A
MX2021001479A MX2021001479A MX2021001479A MX2021001479A MX 2021001479 A MX2021001479 A MX 2021001479A MX 2021001479 A MX2021001479 A MX 2021001479A MX 2021001479 A MX2021001479 A MX 2021001479A MX 2021001479 A MX2021001479 A MX 2021001479A
Authority
MX
Mexico
Prior art keywords
biological
vaccines
medicament
antioxidant
vector
Prior art date
Application number
MX2021001479A
Other languages
English (en)
Inventor
Vincent Edwin Paul Levet
Frédéric Stéphane Mathot
Bram Vuylsteke
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2021001479A publication Critical patent/MX2021001479A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un método para la fabricación de un medicamento biológico que comprende al menos una molécula biológica o un vector, dicho método comprende las siguientes etapas, una o más de las cuales se llevan a cabo en un recinto aséptico que ha sido esterilizado en superficie utilizando peróxido de hidrógeno: (a) formular la molécula biológica o el vector con uno o más excipientes que incluyen un antioxidante, para producir un medicamento biológico que comprende un antioxidante; (b) llenar recipientes con el medicamento biológico; y (c) sellar o sellar parcialmente los recipientes; y medicamentos biológicos, composiciones inmunogénicas y vacunas que comprenden antioxidantes.
MX2021001479A 2018-08-07 2019-08-05 Novedosos procesos y vacunas. MX2021001479A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18187622 2018-08-07
PCT/EP2019/070981 WO2020030572A1 (en) 2018-08-07 2019-08-05 Processes and vaccines

Publications (1)

Publication Number Publication Date
MX2021001479A true MX2021001479A (es) 2021-04-28

Family

ID=63350337

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001479A MX2021001479A (es) 2018-08-07 2019-08-05 Novedosos procesos y vacunas.

Country Status (8)

Country Link
US (1) US20210283238A1 (es)
EP (1) EP3833382A1 (es)
JP (1) JP2021533162A (es)
CN (1) CN112601545A (es)
BR (1) BR112021000965A2 (es)
CA (1) CA3107077A1 (es)
MX (1) MX2021001479A (es)
WO (1) WO2020030572A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201818084D0 (en) * 2018-11-06 2018-12-19 Univ Oxford Innovation Ltd Compositions and methods

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0405867B1 (en) 1989-06-27 1995-03-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Novel compounds
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
CZ289476B6 (cs) 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
ATE226831T1 (de) 1993-05-18 2002-11-15 Univ Ohio State Res Found Impfstoff gegen mittelohrentzündung
ATE195740T1 (de) 1993-11-17 2000-09-15 Om Pharma Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ES2320315T5 (es) 1994-07-15 2012-12-05 University Of Iowa Research Foundation Oligonucleótidos inmunoestimuladores
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
CA2292838A1 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
EP2050465B1 (en) 1997-08-29 2014-06-11 Antigenics Inc. Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
EP1880735A3 (en) 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccine
US7153472B1 (en) * 2000-11-22 2006-12-26 Quadrant Drug Delivery Limited Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
CA2849556A1 (en) * 2002-04-11 2003-10-23 Vu Truong-Le Preservation of bioactive materials by freeze dried foam
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
WO2005063802A2 (en) 2003-12-23 2005-07-14 Children's Hospital, Inc. Haemophilus influenzae type iv pili
US8367099B2 (en) * 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
KR20080042865A (ko) 2005-08-10 2008-05-15 아르네 포르스그렌 아베 모락셀라 카타랄리스와 상피세포, 세포외기질 단백질 및보체계의 상호작용
US20070084144A1 (en) * 2005-10-14 2007-04-19 Atrium Medical Corporation Packaging and sterilization of medical devices
MY150105A (en) 2006-01-17 2013-11-29 Forsgren Arne A novel surface exposed haemophilus influenzae protein (protein e; pe)
EP1964583A1 (en) * 2007-02-09 2008-09-03 Royal College of Surgeons in Ireland Process for producing a collagen/hydroxyapatite composite scaffold
BRPI0821555A2 (pt) * 2007-12-21 2015-06-16 Glaxosmithline Biolog S A Componente para uma vaciana de hiv ou massa, componente ou massa líquida liofilizados, composição farmacêutica ou vacina, usos do componente ou massa final ou da composição farmacêutica e de um antioxidante com pelo menos um grupo funcional tiol e métodos de tratamento e de reconstituição de um componente liofilizado, e kit
KR101617895B1 (ko) 2007-12-24 2016-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 ｒｓｖ 항원
CA2734275A1 (en) * 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
KR101696002B1 (ko) 2009-06-24 2017-01-13 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 ｒｓｖ 항원
RU2585227C2 (ru) 2009-07-15 2016-05-27 Новартис Аг Композиции белка f rsv и способы их получения
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
JP2014519819A (ja) 2011-05-13 2014-08-21 ノバルティス アーゲー 融合前ｒｓｖｆ抗原
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
EP2974734B1 (en) * 2013-03-12 2018-10-10 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
JP6703475B2 (ja) 2013-03-13 2020-06-03 アメリカ合衆国 融合前ｒｓｖｆタンパク質およびそれらの使用
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
US9393298B2 (en) * 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
WO2015057548A1 (en) * 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp Thermostable respiratory synctial virus (rsv) vaccine compositions
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
US10632182B2 (en) * 2014-05-14 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Methods for freeze-drying and rehydrating biologics
BR112017026523A2 (pt) 2015-06-12 2018-08-14 Glaxosmithkline Biologicals Sa vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.
TN2018000154A1 (en) * 2015-10-22 2019-10-04 Modernatx Inc Respiratory syncytial virus vaccine
SG10202001389PA (en) 2015-12-23 2020-04-29 Pfizer Rsv f protein mutants
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
MX2019006349A (es) 2016-12-16 2019-08-22 Inst Res Biomedicine Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
EP3600391A1 (en) 2017-03-31 2020-02-05 GlaxoSmithKline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
CN108018210B (zh) * 2017-12-30 2020-11-06 华中农业大学 一种猪霍乱沙门氏菌疫苗菌株的保藏方法及其专用保护剂

Also Published As

Publication number Publication date
EP3833382A1 (en) 2021-06-16
JP2021533162A (ja) 2021-12-02
BR112021000965A2 (pt) 2021-04-27
CN112601545A (zh) 2021-04-02
US20210283238A1 (en) 2021-09-16
CA3107077A1 (en) 2020-02-13
WO2020030572A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
WO2018142220A3 (en) Medical apparatus and method for sterilizing medical apparatus
MX2024005597A (es) Metodo de esterilizacion.
AR107242A1 (es) Preparación térmica de esporas bacterianas
SG11201801259PA (en) Facial mask aseptic-filling apparatus and Facial Mask Preparation Method Thereof
AR098256A1 (es) Vectores para expresión de antígenos asociados a próstata
MX2017008719A (es) Aparato y metodo para esterilizar endoscopios.
BR112016029240A2 (pt) método para fabricar uma embalagem maleável com bico enchida assepticamente com conteúdos, e, pacote
AR099427A1 (es) Métodos para el envasado aséptico de alimentos de baja acidez
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2015007730A (es) Metodo para obtener una vacuna de mycoplasma.
MY192320A (en) Cap sterilizer, content filling system, cap sterilization method, and content filling method
AU2017262586A1 (en) Improved drug formulations
MX2020011817A (es) Metodos para tratar el linfoma.
WO2018217710A8 (en) Micro-nanobubble solutions for tissue preservation and generation thereof
CL2017000241A1 (es) Aparatos y métodos para envolver un relleno en un producto alimentario
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
PE20150123A1 (es) Producto alimenticio con cultivos vivos
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
MX2021001479A (es) Novedosos procesos y vacunas.
WO2015051371A3 (en) Haemophilus parasuis vaccine serovar type four
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
IN2014DN09993A (es)
WO2010081672A3 (de) Verfahren und vorrichtung zur sterilisation eines oder mehrerer gegenstände
AU2015300258A8 (en) CDCA1-derived peptide and vaccine containing same
MX2019002007A (es) Dispositivo para la esterilizacion de bolsas flexibles mediante irradiacion por haz de electrones y procedimiento de esterilizacion de las mismas.